| Document |
Document Title |
|
WO/2013/152359A1 |
Provided herein, inter alia, are compositions and methods of synthesis and detection of tetrazines and diazonorcaradienes.
|
|
WO/2013/137075A1 |
The present invention provides a compound characterized by being represented by general formula (I) (in formula (I), A's independently represent a halogen atom, an alkyl group, a haloalkyl group, an alkoxy group, a haloalkoxy group, an a...
|
|
WO/2013/129021A1 |
The present invention is a method for producing a 5-substituted-2-aryl-2H-tetrazole that is useful as an intermediate for producing a pharmaceutical compound, and relates to a method which selectively introduces an aryl group in the 2 po...
|
|
WO/2013/124228A1 |
The invention relates to suifin- and sulfonimidoylbenzamides of general formula (S) used as herbizides. In said formula (I), R, R', R", X, W and Z represent radicals such as hydrogen, organic radicals such as alkyl, and other radicals su...
|
|
WO/2013/124238A1 |
The invention relates to sulfinyl aminobenzamides of general formula (I) acting as herbicides. In formula (I), R, R', R", X, W and Z represent groups such as hydrogen, organic groups such as alkyl, and other groups such as halogen. Q rep...
|
|
WO/2013/124245A1 |
The invention relates to 4-nitro-substituted N-(tetrazol-5-yl)-, N-(triazol-5-yl)-, and N-(1,3,4-oxadiazol-2-yl)aryl carboxylic acid amides of the general formula (I) as herbicides. In the formula (I), X, Y, and W represent groups such a...
|
|
WO/2013/117582A1 |
The present invention relates to a process for the preparation of N-hydroxy-l-(l-alkyl-lH-tetrazol-5-yl)-l-phenylmethanimine derivatives of the general formula (I)
|
|
WO/2013/116682A1 |
The invention relates generally to macrocyclic compounds of formula I and their therapeutic use. More particularly, the invention relates to macrocyclic compounds that modulate the activity of IL-17 and/or are useful in the treatment of ...
|
|
WO/2013/108800A1 |
Provided are: a compound having an excellent hypoglycemic activity and an excellent protective activity for a β cell or the pancreas, or a pharmaceutically acceptable salt thereof; and a pharmaceutical composition having an excellent th...
|
|
WO/2013/104705A1 |
Tetrazol-5-yl- and triazol-5-yl-aryl compounds of the general formula (I) are described as herbicides. In this formula (I), X, Z, W and R are radicals such as hydrogen, organic radicals such as alkyl, and other radicals such as halogen. ...
|
|
WO/2013/087577A1 |
The invention relates to N-(1,2,5-oxadiazol-3-yl), N-(1,3,4-oxadiazol-2-yl), N-(tetrazol-5-yl), and N-(triazol-5-yl) aryl carboxylic acid amides of general formula (I) as herbicides. In said formula (I), R, V, X, Y, and Z stand for group...
|
|
WO/2013/083859A2 |
N-(tetrazol-5-yl)- and N-(triazol-5-yl)arylcarboxamides of formula (I) and their use as herbicides. The invention relates to N-(tetrazol-5-yl)- and N-(triazol-5-yl)arylcarboxamides of formula (I) and their use as herbicides. In said form...
|
|
WO/2013/072491A1 |
Specific C-functionalised cyclic bisaminal compounds of formula (I) or (II), the salts or solvents thereof, methods for preparing same, the uses thereof, and methods for preparing functional tetraazacycloalkane compounds implementing suc...
|
|
WO/2013/072924A1 |
The present invention relates to an improved process for the preparation of angiotensin receptor antagonists and intermediates thereof. Particularly the present invention relates to an improved process for the preparation of N-(l-oxopent...
|
|
WO/2013/069545A1 |
Provided is a complex compound which is composed of a compound represented by formula (I), a metal and at least one kind of ion that is selected from the group consisting of ions obtained by adding one or more protons to amines, ammonium...
|
|
WO/2013/064459A1 |
The invention relates to oxime-ether-substituted benzoylamides of general formula (I) as herbicides. In said formula (I), R, X, and Y stand for groups such as hydrogen, organic groups such as alkyl, and other groups such as halogen. Q st...
|
|
WO/2013/064457A1 |
The invention relates to 5-phenyl-substituted N-(tetrazol-5-yl) aryl carboxylic acid amides and N-(triazol-5-yl) aryl carboxylic acid amides of general formula (I) as herbicides. In said formula (I), W, X, Y, Z, and R stand for groups su...
|
|
WO/2013/064458A1 |
The invention relates to herbicide/safener compositions that contain herbicidal active ingredients from the group of N-(tetrazol-5-yl) aryl carboxylic acid amides and N-(triazol-5-yl) aryl carboxylic acid amides and safeners. Said herbic...
|
|
WO/2013/056163A1 |
Disclosed herein inter alia are Boron containing compounds and methods for treating infections related to antibiotic resistant microorganisms.
|
|
WO/2013/056079A1 |
Inhibitors of beta lactamases and their use in treating bacterial infections are dicslosed.
|
|
WO/2013/050512A1 |
The invention relates to a method for functionalizing an electrically conductive substrate, which is not a substrate made of gold, via a layer of chemical compounds, said method comprising the following steps: - a step in which the elect...
|
|
WO/2013/045431A1 |
The present invention is directed to novel retinoid-related orphan receptor gamma (RORy) modulators of formula (I), processes for their preparation, pharmaceutical compositions containing these modulators, and their use in the treatment ...
|
|
WO/2013/039187A1 |
[Problem] To provide a compound useful as a renal disease preventive and/or therapeutic agent. [Solution] The inventors of the present invention investigated compounds having a trypsin inhibitory activity, verified that a guanidinobenzoi...
|
|
WO/2013/031776A1 |
Provided are a battery electrolyte which exhibits excellent ion conductivity, a method for producing the battery electrolyte, and a battery comprising the electrolyte. The battery electrolyte is characterized by containing a mesoionic co...
|
|
WO/2013/026768A1 |
The invention relates to an energetic active composition comprising a dihydroxylammonium salt or diammonium salt of 5,5'- bistetrazole-1,1'-diol, 5,5'-bistetrazole-1,2'-diol or 5,5'-bistetrazole-2,2'-diol or a mixture of at least two of ...
|
|
WO/2013/025733A1 |
Compounds, methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds, and methods of using such compounds to treat, prevent or diagnose diseases, disorders, or conditions associated with one ...
|
|
WO/2012/148148A9 |
The present invention relates to a novel zinc azide complex. The present invention also relates to a process for preparing 5-substituted-1H-tetrazole derivatives from nitrile derivatives by using the zinc azide complex. According to the ...
|
|
WO/2013/017559A1 |
N-(tetrazol-5-yl)- and N-(triazol-5-yl)arylcarboxamides of the general formula (I) are described as herbicides. In this formula (I), X, Y, Z and R represent radicals such as hydrogen, organic radicals such as alkyl, and other radicals su...
|
|
WO/2013/010488A1 |
The present invention relates to the field of pharmaceutical chemistry, specifically relates to a statin intermediate having formula (I) and preparation thereof. The advantages of the method used to prepare the chiral sulfone intermediat...
|
|
WO/2013/001235A1 |
The present invention relates to a supported alkoxylated organotin reactant, to the process for preparing same, to the use of such a reactant as a catalyst for heterogeneous-phase organic synthesis, and also to a process for heterogeneou...
|
|
WO/2012/165550A1 |
Provided is a liquid crystal alignment layer of which a constituent member is a compound represented by general formula (I).
|
|
WO/2012/154249A1 |
In one aspect, the invention relates to compounds having the formula: where R1, R2a, R2b, R3-R6, a, b, Z, and X are as defined in the specification, or a pharmaceutically acceptable salt thereof. These compounds have neprilysin inhibitio...
|
|
WO/2012/151539A2 |
The invention relates to compositions of DOTA derivative compounds, lanthanoid-DOTA derivative molecular complex, and lanthanoid-complex encapsulated solid lipid particles or capsules, and methods of making and using the compositions. Th...
|
|
WO/2012/147952A1 |
The present invention provides a cathode catalyst for an air secondary battery having both excellent oxygen reduction activity and water oxidation activity. Also provided is an air secondary battery using said catalyst. The present inven...
|
|
WO/2012/143588A1 |
The invention relates to compounds having formula (I), in which the meaning of the substituents is that indicated in the description. Said compounds can be used as fluorescent markers.
|
|
WO/2012/143355A1 |
What is described is a process for producing high-purity gadobutrol in a purity (according to HPLC) of more than 99.7or 99.8 or 99.9% and the use for preparing a pharmaceutical formulation for parenteral administration. The process is ca...
|
|
WO/2012/142702A1 |
Described herein is a contrast agent for administration to a subject. The contrast agent includes a targeting portion that includes an unchelated aminocarboxylate functional group; a metal ion bound to a metal-complexable portion; and a ...
|
|
WO/2012/145361A1 |
The present invention relates to compounds of Formula I and pharmaceutically acceptable salts, solvates, and hydrates thereof, that are useful as single pharmaceutical agents or in combination with one or more additional pharmaceutical a...
|
|
WO/2012/129452A2 |
This invention discloses a series of novel propynoic acid carbamoyl methyl-amides (PACMAs), methods for synthesizing the PACMAs and pharmaceutical compositions containing the PACMAs. These novel compounds and compositions show cytotoxici...
|
|
WO/2012/120234A1 |
The present invention relates to a exposure kit including (A) a cyanoacrylate and (B) a fluorescent agent having a molecular weight of less than 400 g.mol-1, a sublimation temperature of less than 200 °C, and a coefficient of extinction...
|
|
WO/2012/116452A1 |
Among other things, in general, antimicrobial and/or adjuvant compounds are provided according to Formula la: (Ia) in which E and R1-11 have the meanings described herein; and prodrugs and pharmaceutically acceptable salts thereof. Other...
|
|
WO/2012/103333A1 |
Described herein are tetrazole compounds and their use in treating medical disorders, such as obesity. Pharmaceutical compositions and methods of making various tetrazole compounds are provided. The compounds are contemplated to have act...
|
|
WO/2012/082857A1 |
In one aspect, the invention relates to compounds having the formula: (I) where R1-R6, a, b, and X are as defined in the specification, or a pharmaceutically acceptable salt thereof. These compounds have neprilysin inhibition activity. I...
|
|
WO/2012/082853A1 |
In one aspect, the invention relates to compounds having the formula: where R1-R6, a, b, and X are as defined in the specification, or a pharmaceutically acceptable salt thereof. These compounds have neprilysin inhibition activity. In an...
|
|
WO/2012/065953A1 |
The present invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof, wherein R1, R2, R3, R4, R5, B, X, m and n are defined herein. The invention also relates to a method for manufacturing the compounds ...
|
|
WO/2012/056294A1 |
Disclosed herein is an improved process for the preparation of pure N-Pentanoyl-N-[[2'- (1h-Tetrazol-5-Y1)[1,1'-Biphenyl]-4-Yl]Methyl]-L-Valine employing highly active carbon.
|
|
WO/2012/050041A1 |
The present invention provides a pest control agent, an acaricide, or a bactericide that contains, as the active ingredient thereof, at least one type of compound selected from aryloxyurea compounds represented by formula (V) (wherein R1...
|
|
WO/2012/046771A1 |
The inventors have intensively studied on compounds that have Aβ42 production inhibitory activity and have found that a compound (I) of the present invention, wherein a carboxylic acid or a tetrazole group is bonded to a cycloalkane moi...
|
|
WO/2012/043933A1 |
The present invention relates to a MRI contrast agent having a gadolinium complex, and more specifically, to a DO3A-tranexamic acid having a structure of chemical formula 1 or ester compound thereof. The present invention enables prepara...
|
|
WO/2012/035171A2 |
A compound of formula (I), wherein A is S, O or a double bond, and L is a substituted thiazolyl, phenyl or pyridyl. The compound is useful for the treatment of inflammation and cancer.
|
